[{"address1": "400 Spectrum Center Drive", "address2": "Suite 2040", "city": "Irvine", "state": "CA", "zip": "92618", "country": "United States", "phone": "949 409 3700", "website": "https://cgoncology.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-na\u00efve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Arthur  Kuan", "age": 32, "title": "Chairman & CEO", "yearBorn": 1991, "fiscalYear": 2023, "totalPay": 640974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ambaw  Bellete M.S.", "age": 52, "title": "President & COO", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1061210, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vijay  Kasturi M.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 299688, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Corleen M. Roche", "age": 56, "title": "CFO & Secretary", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Steele", "title": "Vice President of Finance, Accounting & Administration", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Swapnil  Bhargava Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua F. Patterson", "age": 47, "title": "General Counsel & Chief Compliance Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bing  Kung", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 36.49, "open": 36.59, "dayLow": 35.93, "dayHigh": 37.8, "regularMarketPreviousClose": 36.49, "regularMarketOpen": 36.59, "regularMarketDayLow": 35.93, "regularMarketDayHigh": 37.8, "forwardPE": -20.983242, "volume": 419350, "regularMarketVolume": 419350, "averageVolume": 558261, "averageVolume10days": 514020, "averageDailyVolume10Day": 514020, "bid": 37.53, "ask": 37.66, "bidSize": 200, "askSize": 100, "marketCap": 2519412224, "fiftyTwoWeekLow": 25.77, "fiftyTwoWeekHigh": 50.23, "priceToSalesTrailing12Months": 4674.2344, "fiftyDayAverage": 33.9648, "twoHundredDayAverage": 36.337273, "currency": "USD", "enterpriseValue": 1895115520, "floatShares": 44666588, "sharesOutstanding": 67077000, "sharesShort": 6982104, "sharesShortPriorMonth": 5853407, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1041, "heldPercentInsiders": 0.07002, "heldPercentInstitutions": 0.79619, "shortRatio": 11.09, "shortPercentOfFloat": 0.105100006, "bookValue": 8.286, "priceToBook": 4.532947, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -72329000, "trailingEps": -1.14, "forwardEps": -1.79, "enterpriseToRevenue": 3515.984, "enterpriseToEbitda": -27.796, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CGON", "underlyingSymbol": "CGON", "shortName": "CG Oncology, Inc.", "longName": "CG Oncology, Inc.", "firstTradeDateEpochUtc": 1706193000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8a3d3fd0-b24c-3632-b8df-103b951d4052", "gmtOffSetMilliseconds": -14400000, "currentPrice": 37.56, "targetHighPrice": 86.0, "targetLowPrice": 52.0, "targetMeanPrice": 67.57, "targetMedianPrice": 65.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 552880000, "totalCashPerShare": 8.242, "ebitda": -68180000, "totalDebt": 355000, "quickRatio": 56.757, "currentRatio": 57.954, "totalRevenue": 539000, "debtToEquity": 0.064, "revenuePerShare": 0.036, "operatingCashflow": -63705000, "operatingMargins": -232.9099, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]